A multicentre UK study of adults with inflammatory bowel disease (IBD) compared with healthy individuals as controls assessed the effect of several immunosuppressive IBD treatments on immune responses to SARS-CoV-2 vaccines. Participants who had all received two doses of the Pfizer–BioNTech BNT162b2, the Moderna mRNA-1273 or the AstraZeneca–University of Oxford ChAdOx1 nCoV-19 vaccines were recruited (n = 483), and antibody responses were measured 53–92 days after second vaccine dose. In patients with IBD, the antibody response of SARS-CoV-2 vaccines did vary according to immunosuppressive drug regimen and was lower in patients receiving infliximab, infliximab plus thiopurines, or tofacitinib than in healthy individuals as controls.